CNS Disorders  >>  Vraylar (cariprazine)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
2020-005726-29: An open label signal detection study to evaluate the effects of cariprazine on cognitive functioning in patients with schizophrenia in need of adjustment of oral antipsychotic treatment

Not yet recruiting
4
20
Europe
Capsule, hard, Reagila
Medical University Innsbruck, Gedeon Richter Plc.
Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2021-001268-58: Investigation of effects of cariprazine in patients with mitochondrial schizophrenia A cariprazine hatásának vizsgálata mitochondriális dysfunkcióval asszociált schizophreniában

Not yet recruiting
4
10
Europe
Reagila, Capsule, Reagila
Semmelweis University, STIA-POC-2020, Semmelweis University, STIA-POC-2020, Gedeon Richter
Mitochondrial disease associated schizophrenia Mitochondrialis betegséghez társuló schizophrenia, schizophrenia associating with mitochondrial disease schizophrenia, amely mitochondrialis betegséghez társul, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04]
 
 
NCT05384483: Cariprazine Versus Placebo for Social Anxiety Disorder

Not yet recruiting
4
40
US
Cariprazine, Vraylar®, Placebo
The Medical Research Network, AbbVie
Social Anxiety Disorder
10/23
11/23

Download Options